Persistent Multiyear Control of Relapsed T-Cell Acute Lymphoblastic Leukemia With Successive Donor Lymphocyte Infusions: A Case Report
Corresponding Author
Jeffrey S. Huo MD, PhD
Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
Correspondence to: Jeffrey S. Huo, Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University School of Medicine, Bloomberg 11379, 1800 Orleans Street, Baltimore, MD 21287. E-mail: [email protected]
Search for more papers by this authorHeather J. Symons MD, MHS
Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
Search for more papers by this authorNancy Robey PA
Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
Search for more papers by this authorMichael J. Borowitz MD, PhD
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland
Search for more papers by this authorEric S. Schafer MD, MHS
Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
Search for more papers by this authorAllen R. Chen MD, PhD, MHS
Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
Search for more papers by this authorCorresponding Author
Jeffrey S. Huo MD, PhD
Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
Correspondence to: Jeffrey S. Huo, Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University School of Medicine, Bloomberg 11379, 1800 Orleans Street, Baltimore, MD 21287. E-mail: [email protected]
Search for more papers by this authorHeather J. Symons MD, MHS
Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
Search for more papers by this authorNancy Robey PA
Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
Search for more papers by this authorMichael J. Borowitz MD, PhD
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland
Search for more papers by this authorEric S. Schafer MD, MHS
Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
Search for more papers by this authorAllen R. Chen MD, PhD, MHS
Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
Search for more papers by this authorConflict of interest: Nothing to declare.
Abstract
There are few therapeutic options for patients with T-cell acute lymphoblastic leukemia (T-ALL) who have recurrent disease after initial matched sibling hematopoietic stem cell transplantation. While a second hematopoietic stem cell transplant (HSCT) from a haploidentical donor offers the conceptual possibility of greater graft versus leukemia effect, there is minimal literature to describe the efficacy of this approach in recurrent pediatric T-ALL. We present the case of a now 9-year-old female in whom second haploidentical HSCT, followed by successive donor lymphocyte infusions in response to minimal residual disease reemergence, has led to 3+ years of ongoing disease control without graft versus host disease and excellent quality of life.
REFERENCES
- 1Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, Ferrando A, Fielding AK, Goldstone AH, Ketterling RP, Litzow MR, Luger SM, McMillan AK, Mansour MR, Rowe JM, Tallman MS, Lazarus HM. T-cell acute lymphoblastic leukemia in adults: Clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood 2009; 114: 5136–5145.
- 2Reismuller B, Peters C, Dworzak MN, Potschger U, Urban C, Meister B, Schmitt K, Dieckmann K, Gadner H, Attarbaschi A, Mann G. Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): A population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Munster) study group. J Pediatr Hematol Oncol 2013; 35: e200–e204.
- 3Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood 2015; 126: 983–992.
- 4Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolanos-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.
- 5Zeidan AM, Forde PM, Symons H, Chen A, Smith BD, Pratz K, Carraway H, Gladstone DE, Fuchs EJ, Luznik L, Jones RJ, Bolanos-Meade J. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2014; 20: 314–318.
- 6Tan Y, Du K, Luo Y, Shi J, Cao L, Zheng Y, Zheng G, Zhao Y, Ye X, Cai Z, Huang H. Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Transfusion 2014; 54: 1493–1500.
- 7Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer 2015; 62: 1176–1183.
- 8Porwit-MacDonald A, Bjorklund E, Lucio P, van Lochem EG, Mazur J, Parreira A, van den Beemd MW, van Wering ER, Baars E, Gaipa G, Biondi A, Ciudad J, van Dongen JJ, San Miguel JF, Orfao A. BIOMED-1 concerted action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia 2000; 14: 816–825.
- 9Bar M, Wood BL, Radich JP, Doney KC, Woolfrey AE, Delaney C, Appelbaum FR, Gooley TA. Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. Leuk Res Treatment 2014; 2014: 421723.
- 10Wu D, Sherwood A, Fromm JR, Winter SS, Dunsmore KP, Loh ML, Greisman HA, Sabath DE, Wood BL, Robins H. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med 2012; 4: 134ra163.
- 11Whitlock J, dalla Pozza L, Goldberg JM, Silverman LB, Ziegler DS, Attarbaschi A, Brown P, Gardner RA, Gaynon PS, Hutchinson RJ, Marcus LJ, Messinger YH, Schultz KR, Vandergiessen J, Eckroth E, Locatelli F, Zwaan CM, Wood BL, Sposto R, Gore L. Nelarabine in combination with etoposide and cyclophosphamide is active in first relapse of childhood T-acute lymphocytic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LL). Blood 2014; 124: 795–795.
- 12Horton TM, Lu X, O'Brien MM, Borowitz MJ, Devidas M, Raetz EA, Brown PA, Zeng H, Hunger S, Whitlock J. Bortezomib reinduction therapy improves response rates in pediatric ALL in first relapse: A Children's Oncology Group (COG) study (AALL07P1). J Clin Oncol 2013; 31(Suppl): abstr 10003.
- 13Symons HJ, Leffell MS, Rossiter ND, Zahurak M, Jones RJ, Fuchs EJ. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2010; 16: 533–542.
- 14Symons HJ, Chen A, Gamper C, Cooke KR, Showel M, Bolanos-Meade J, Luznik L, Jones RJ, Fuchs EJ. Haploidentical BMT using fully myeloablative conditioning, T cell replete bone marrow grafts, and post-transplant cyclophosphamide (PT/Cy) has limited toxicity and promising efficacy in largest reported experience with high risk hematologic malignancies. Biol Blood Marrow Transplant 2015; 21(2, Supplement): S29.
- 15Shah NN, Borowitz MJ, Robey NC, Gamper CJ, Symons HJ, Loeb DM, Wayne AS, Chen AR. Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia. Biol Blood Marrow Transplant 2014; 20: 1000–1007.
- 16McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolanos-Meade J, Rosner GL, Kanakry CG, Perica K, Symons HJ, Brodsky RA, Gladstone DE, Huff CA, Pratz KW, Prince GT, Dezern AE, Gojo I, Matsui WH, Borrello I, McDevitt MA, Swinnen LJ, et al. Risk-stratified outcomes of nonmyeloablative, HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 2015; 125: 3024–3031.
